Bicycle Therapeutics Q2 2026 Earnings Report

Bicycle Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.58
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Bicycle Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $4.22 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Bicycle Therapeutics Announcement Details

• Quarter: Q2 2026
• Date: 8/7/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Bicycle Therapeutics (NASDAQ:BCYC) plc (NASDAQ:BCYC) is a clinical-stage biopharmaceutical company developing medicines based on its proprietary Bicycle technology. The platform uses small, constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and manufacturing advantages of small molecules with the target specificity often associated with larger biologic medicines.

The company’s research and development activities are focused primarily on oncology. Its pipeline includes Bicycle toxin conjugates, which are designed to deliver cancer-killing payloads to tumor cells, as well as Bicycle molecules intended to modulate immune targets and support other targeted therapeutic approaches. Bicycle Therapeutics has also pursued collaborations and partnered programs to apply its platform across a range of disease areas.

Bicycle Therapeutics was founded in 2009 based on research originating at the University of Cambridge and maintains operations in Cambridge, England, and the United States. The company’s programs are developed for potential use in international markets, although most remain in clinical or preclinical development and are subject to regulatory review. Kevin Lee serves as the company’s president and chief executive officer.